SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.
Authors
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-2919-4326)
- Andrea M. Gross (ORCID: https://orcid.org/0000-0003-1646-4531)
- K. Ballman
- Aerang Kim
- Nahoko Sato (ORCID: https://orcid.org/0000-0002-4052-7240)
- Angela C. Hirbe (ORCID: https://orcid.org/0000-0003-1719-0771)
- Rachel S. Heise (ORCID: https://orcid.org/0000-0002-7785-4579)
- Natalie B. Collins (ORCID: https://orcid.org/0000-0003-2980-9244)
- J. Shern
- Min-Jung Lee
- Karen M. Cichowski
- Christian F. Meyer (ORCID: https://orcid.org/0000-0003-3329-7106)
- Rena R. Xian (ORCID: https://orcid.org/0000-0001-5532-6524)
- Shraddha Rastogi (ORCID: https://orcid.org/0000-0003-0680-0407)
- Denise Reinke
- B. C. Widemann
- Geraldine O'Sullivan Coyne
- Shirin Shahsavari
- Pamela L. Wolters
- Roshan L. Shrestha
- R. Taylor. Sundby
- Liza Lindenberg
- Eva Dombi
- Brian A. Van Tine
Institutions
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Children's National (US)
- Johns Hopkins University (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- University of Michigan (US)
- Alliance for Clinical Trials in Oncology (US)
- Johns Hopkins Medicine (US)
- Michigan Medicine (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2887
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00